Brain Cancer Trial, Recruiting NCT05768087 Sponsor: University of Aarhus Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT05768087
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a specific type of brain tumour called glioblastoma (GBM), confirmed using the latest medical classification system (WHO 2021).
  • People who have undergone the safest possible level of surgery to remove the tumour — any amount of surgery is acceptable, including a biopsy where only a small sample is taken.
  • People whose tumour size and location make them suitable for a standard course of radiation therapy combined with chemotherapy (60 Gy).
  • People where there is at least 5 mm of distance between the tumour treatment area and certain sensitive structures nearby, such as the brainstem, the part of the eye that connects to the brain, and related vision pathways — as measured on an MRI scan.
  • People aged 18 or older.
  • People who have a reasonably good level of physical functioning, as rated on a standard medical scale (Karnofsky Performance Status of 70 or above — confirm with trial site if unsure what this means for a specific situation).
  • People whose blood test results are considered acceptable by their treating doctor.
  • People who have no medical reasons preventing them from having an MRI scan or receiving a contrast dye used during MRI imaging.
  • People who have provided written agreement to take part in the trial before being registered, in line with standard research and local regulations.

Who may not be able to join:

  • The trial does not list separate exclusion criteria — eligibility is based entirely on whether the inclusion criteria above are met. People who do not meet one or more of the above criteria may not be eligible (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anouk K Trip, MD PhD, Danish Centre for Particle Therapy

Phone: +4529797231

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 April 2024
Est. completion
1 October 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Adverse Events; Dose Limiting Toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov